Frequent Germ-line Mutations of the MEN1, CASR, and HRPT2/CDC73 Genes in Young Patients with Clinically Non-familial Primary Hyperparathyroidism
Overview
Authors
Affiliations
Familial primary hyperparathyroidism (FPHPT) may occur due to an underlying germ-line mutation in the MEN1, CASR, or HRPT2/CDC73 genes. The disease may be undiagnosed in the absence of a history suggestive of FHPT. Young PHPT patients (≤45 years of age) are more likely to harbor occult FPHPT. A total of 1,161 (136 were ≤45 years of age) PHPT patients underwent parathyroidectomy from 2001 to 2009. Thirty-four patients declined participation. Sixteen patients were diagnosed in the clinical routine with FPHPT (11 MEN1, four MEN2A, and one HPT-JT) and were not included in the genetic analysis. Eighty-six young (≤45 years of age) patients with clinically non-syndromic PHPT underwent genetic analysis. Sanger sequencing of all coding regions of the MEN1, CASR, and the HRPT2/CDC73 genes was performed. Eight of 86 (9.3%) young patients with clinically non-familial PHPT displayed deleterious germ-line mutations in the susceptibility genes (4 MEN1, 3 CASR, and 1 HRPT2/CDC73). There was one insertion, one deletion, two nonsense, and four missense mutations, all predicted to be highly damaging to protein function and absent in 3,244 control chromosomes. Germ-line mutations in known susceptibility genes within young patients with PHPT, including those diagnosed in the clinical routine, was 24/102 (23.5%; 15 MEN1, four RET, three CASR, and two HRPT2/CDC73). We demonstrate that germ-line inactivating mutations in susceptibility genes are common in young patients with clinically non-familial PHPT. Thus, enhanced use of genetic analysis may be warranted in clinically non-familial young PHPT patients.
Needleman L, Chun N, Sitaraman S, Tan M, Sellmeyer D, Kebebew E JBMR Plus. 2024; 9(1):ziae149.
PMID: 39677927 PMC: 11646312. DOI: 10.1093/jbmrpl/ziae149.
Hangge P, Dream S, Yen T, Doffek K, Stachowiak S, Shaker J Ann Surg Oncol. 2024; 31(6):3964-3971.
PMID: 38459417 DOI: 10.1245/s10434-024-15104-3.
Targeting GABARAPL1/HIF-2a axis to induce tumor cell apoptosis in nasopharyngeal carcinoma.
Huang X, Zhou L, Chen J, Zhang S Iran J Basic Med Sci. 2024; 27(2):157-164.
PMID: 38234672 PMC: 10790296. DOI: 10.22038/IJBMS.2023.72952.15863.
Mazarico-Altisent I, Capel I, Baena N, Bella-Cueto M, Barcons S, Guirao X Front Endocrinol (Lausanne). 2023; 14:1244361.
PMID: 37810884 PMC: 10558207. DOI: 10.3389/fendo.2023.1244361.
Faggiano A, Fazzalari B, Mikovic N, Russo F, Zamponi V, Mazzilli R Genes (Basel). 2023; 14(9).
PMID: 37761922 PMC: 10531237. DOI: 10.3390/genes14091782.